AstraZeneca Completes Enrolment in a Further Two Pivotal Phase III Studies for 
Vandetanib (ZACTIMA(TM)) in Non-Small Cell Lung Cancer (NSCLC)

ALDERLEY PARK, England


FOR NON-US HEALTHCARE PROFESSIONAL PRESS ONLY

AstraZeneca (LSE: AZN)(NYSE: AZN) announced today that it has completed 
enrolment in a further two pivotal Phase III trials for investigational 
once-daily oral anti-cancer drug, vandetanib. Results from these two Phase 
III studies, ZODIAC and ZEAL, are expected later this year.

ZODIAC (ZACTIMA in combination with Docetaxel In non-smAll cell lung
Cancer) is a randomised, double-blind, multi-centre Phase III study to assess 
the efficacy of vandetanib 100mg once daily plus docetaxel versus docetaxel 
alone in 1,380 patients with locally advanced or metastatic NSCLC after 
failure of first-line anti-cancer therapy.

ZEAL (ZACTIMA Efficacy with Alimta in Lung cancer) is a randomised,
double-blind, multi-centre Phase III study to assess the efficacy of
vandetanib100mg once daily plus pemetrexed versus pemetrexed alone in 510
patients with locally advanced or metastatic NSCLC, after failure of
first-line anti-cancer therapy.

ZEST (ZACTIMA Efficacy Study versus Tarceva), which is investigating
vandetanib versus erlotinib, was the first Phase III study to complete
enrollment in November 2007.

"NSCLC is an area of high unmet medical need, and we hope vandetanib will
offer a beneficial new treatment option that will improve the lives of people
with lung cancer," said Dr Peter Langmuir, Medical Science Director at
AstraZeneca.

ZODIAC and ZEAL are part of a comprehensive Phase III clinical trial
programme to gain a broad understanding of how vandetanib may benefit people
with lung cancer. The other study (currently recruiting) is ZEPHYR
(vandetanib + best supportive care [BSC] versus BSC).

The extensive Phase III programme in NSCLC follows promising results from
two Phase II trials where vandetanib demonstrated encouraging anti-tumour
activity when used alone or in combination with standard chemotherapy
(docetaxel).(1;2) Vandetanib has also shown promising early data in 
hereditary medullary thyroid cancer and has been given FDA and EU orphan drug 
status, and FDA fast track designation for this indication.

Vandetanib (ZACTIMA(TM))

- ZACTIMA is a new oral anti-cancer drug being investigated in clinical
trials to assess its impact on the lives of patients with lung and thyroid
cancer.

- Studies have already shown that use of ZACTIMA both on its own and in
combination with chemotherapy gives additional time to patients before their
disease progresses.(1-3)

- ZACTIMA has a unique profile that fights cancer through two clinically
proven mechanisms - by blocking the development of tumour blood supply, and
by blocking the growth and survival of the tumour itself.(4;5)

- Studies to date have shown that ZACTIMA has a manageable side effect
profile.(1-3)

- ZACTIMA's potential benefits in other cancers are also being explored.

ZACTIMA(TM) is a trademark of the AstraZeneca group of companies.

Notes to Editors

About lung cancer

- Over 1.35 million new cases of lung cancer are diagnosed every year and
nearly 1.2 million people die as a result of this devastating disease - more
than breast, colon and prostate cancer combined.(6)

- If lung cancer is detected at early stages, before it has spread to
other organs or lymph nodes, around half of patients can survive for five
years or more. However, few lung cancers are found at this early stage and it
is normally diagnosed at the advanced stage, when five year survival falls to
approximately 15%.(7)

About thyroid cancer

- Thyroid cancer is a rare disease with an estimated 30,000 new cases
diagnosed every year in the USA.(8)

- Medullary thyroid cancer is a specific form of thyroid cancer
accounting for 3 -10% of all thyroid cancers and of these, around a quarter
are hereditary.(6)

About AstraZeneca

- AstraZeneca is a major international healthcare business engaged in
research, development, manufacturing and marketing of prescription
pharmaceuticals and supplier for healthcare services. AstraZeneca is one of
the world's leading pharmaceutical companies with healthcare sales of US
$29.55 billion and is a leader in gastrointestinal, cardiovascular,
neuroscience, respiratory, oncology and infection product sales. AstraZeneca
is listed in the Dow Jones Sustainability Index (Global) as well as the
FTSE4Good Index.

- For more information about AstraZeneca, please visit:
http://www.astrazeneca.com

For further information, please contact: 
Carrie Deverell, 
AstraZeneca, 
Tel: +44-(0)1625-514-77, 
Mobile: +44-(0)7929-845-108, 
carrie.deverell@astrazeneca.com

Reference List

 (1) Natale RB et al. ZD6474 versus gefitinib in
patients with advanced NSCLC: Final results from two-part, double-blind
randomized phase II trial. Journal of Clinical Oncology, Vol 24, No. 18S:
7000. 2006

 (2) Heymach JV et al. Randomized, Placebo-Controlled
Phase II Study of Vandetanib Plus Docetaxel in Previously Treated
Non-Small-Cell Lung Cancer.Journal of Clinical Oncology, Vol 25, No 27, 2007:
pp. 4270-4277.

 (3) Johnson B. et al.Randomized Phase II study of
vandetanib alone or in combination with carboplatin and paclitaxel as
1st-line treatment for advanced NSCLC. J Thoracic Oncol 2007;2(8 Suppl
S):S358-9, Abs C1-02.

 (4) Wedge S.R et al. ZD6474 inhibits vascular
endothelial growth factor signaling, angiogenesis, and tumor growth following
oral administration. Cancer Res 2002;62(16):4645-55.

 (5) Holden SN, Eckhardt SG, Basser R et al. Clinical
evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor
signaling, in patients with solid, malignant tumors. Ann Oncol 2005;
16(8):1391-1397.

 (6) Ferlay J BFPPea. GLOBOCAN 2002: Cancer Incidence,
Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0. Lyon:
IARC Press, 2004.

 (7) Bepler G. Lung cancer epidemiology and genetics. J
Thorac Imaging 1999; 14(4):228-234.

 (8) Ries LAG ea. SEER Cancer Statistics Review,
1975-2001. National Cancer Institute: Bethesda, MD. 2004.